flâneur

Healthcare M&A 2024: Recent Deals and Trends

finalis.com · 1,046 words · saved by 1 readers

Tailored for healthcare enthusiasts, this article provides insights from experts on the dynamic landscape of healthcare M&A. Learn about the latest healthcare M&A deals and gain valuable insights relevant to investment bankers in the capital markets. Kaufman Hall, a healthcare management consulting firm, reported a notable uptick in healthcare M&A deals in Q1 2024 compared to the previous three quarters. This finding was reinforced by an article from Leerink Partners, a prominent investment bank catering to healthcare and life science companies focused on innovation and growth. In their article published on April 16, 2024, Leerink Partners affirmed that Healthcare M&A activity maintained its strength in Q1 2024, with 29 transactions recorded, up from 28 in Q1 2023. According to Dealogic data on healthcare M&A deals, within the 29 transactions recorded year-to-date in 2024, biopharma accounted for 13, services for 10, MedTech for 4, life sciences tools/diagnostics for 2, and healthcare

Tailored for healthcare enthusiasts, this article provides insights from experts on the dynamic landscape of healthcare M&A. Learn about the latest healthcare M&A deals and gain valuable insights relevant to investment bankers in the capital markets. Key takeaways about healthcare M&A in 2024 Increased activity: healthcare M&A saw a notable uptick in Q1 2024, with 29 transactions recorded, indicating sector strength. Biopharma dominance: biopharma remains the most active subsector, comprising 45% of deal volume, with a focus on oncology and inflammation & immunology. Recent healthcare…

related reading